D. Lew

发表

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Robert B Livingston, Gordan Srkalovic, Brian Leyland-Jones, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Recombinant Human Interleukin-4 in Patients With Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study

G. Weiss, S. Dakhil, R. P. Whitehead, 2002, Journal of immunotherapy.

Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.

J. Unger, H. Greenlee, K. Crew, 2015, Journal of acupuncture and meridian studies.

Title Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients Permalink

J. Unger, H. Greenlee, K. Crew, 2022 .

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

C. Hudis, S. Martino, A. Wolff, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

L. Minasian, C. Moinpour, J. Unger, 2018, Journal of the National Cancer Institute.

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

G. Hortobagyi, L. Minasian, C. Moinpour, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S5-06: Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)

C. Moinpour, J. Unger, L. Fehrenbacher, 2017 .

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

G. Hortobagyi, C. Moinpour, W. Barlow, 2016, Breast Cancer Research and Treatment.

Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131)

E. Perez, G. Hortobagyi, L. Pusztai, 2015 .

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.

E. Perez, G. Hortobagyi, R. Livingston, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

E. Winer, B. Leyland-Jones, R. Livingston, 2013 .

Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.

G. Hortobagyi, R. Livingston, W. Barlow, 2012, The oncologist.

Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.

G. Hortobagyi, R. Livingston, W. Barlow, 2019, Journal of the National Cancer Institute.

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2011, Breast Cancer Research and Treatment.

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.

G. Hortobagyi, R. Livingston, W. Barlow, 2015 .

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102

G. Hortobagyi, R. Livingston, W. Barlow, 2013, Breast Cancer Research and Treatment.

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

J. Eastham, B. Redman, E. Small, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

S. Balcerzak, W. Samlowski, E. Crawford, 1998, Investigational New Drugs.

hsp7O: Lack of Correlation with Response to Tamoxifen and Clinical Course of Disease in Estrogen Receptor-positive Metastatic Breast Cancer (A Southwest Oncology Group Study)’

S. Martino, R. Elledge, G. Clark, 2005 .

Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2008 .

SWOG S0102: A phase II study of docetaxel (DOC) and vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer

R. Livingston, W. Barlow, J. Gralow, 2005 .

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2019, The New England journal of medicine.

Combination anastrozole and fulvestrant in metastatic breast cancer.

Robert B Livingston, Rita S Mehta, Daniel F Hayes, 2012, The New England journal of medicine.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, The New England journal of medicine.

Infusional interleukin‐2 and 5‐fluorouracil with subcutaneous interferon‐α for the treatment of patients with advanced renal cell carcinoma

R. Figlin, E. Crawford, P. Triozzi, 2000, Cancer.

Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).

C. Osborne, S. Martino, R. Elledge, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain

L. Minasian, J. Unger, H. Greenlee, 2022, JAMA network open.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial

L. Minasian, J. Unger, H. Greenlee, 2018, JAMA.

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

G. Hortobagyi, L. Pusztai, E. Swisher, 2023, The Lancet. Oncology.

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.

C. Osborne, S. Martino, P. Ravdin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III double-blind clinical trial (S1600) evaluating the effect of immune-enhancing nutrition on radical cystectomy outcomes.

J. Unger, J. Holzbeierlein, M. Fisch, 2018 .

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

S. Martino, R. Livingston, W. Barlow, 2009, The Lancet.

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

H. Linden, S. Martino, C. Shapiro, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil, vincristine, and prednisone compared with single‐agent L‐phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes

S. Martino, C. Osborne, S. Green, 2003, Cancer.

Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)

E. Perez, G. Hortobagyi, S. Martino, 2009, Breast Cancer Research and Treatment.

Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008)

Sheri J. Hartman, J. Unger, J. Gralow, 2018, Obesity.

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

G. Hortobagyi, L. Pusztai, E. Swisher, 2020 .

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

A. Gown, G. Hortobagyi, R. Livingston, 2008, Clinical breast cancer.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

E. Perez, G. Hortobagyi, L. Pusztai, 2016, Breast Cancer Research and Treatment.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

C. Moinpour, J. Unger, L. Fehrenbacher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS4-04: Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200)

L. Minasian, J. Unger, H. Greenlee, 2018 .

Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.

C. Moinpour, J. Unger, J. Gralow, 2019, Journal of Clinical Oncology.

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812)

P. Brown, L. Minasian, L. Ford, 2019, Cancer Prevention Research.

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

L. Minasian, C. Moinpour, J. Unger, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.

C. Moinpour, J. Unger, J. Gralow, 2020, JAMA oncology.

Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.

J. Berlin, P. Philip, E. Swisher, 2019, Journal of Clinical Oncology.

SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally advanced breast cancer

E. Perez, G. Hortobagyi, L. Pusztai, 2016 .

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Razelle Kurzrock, Antje Hoering, Vincent Chung, 2013, Cancer Chemotherapy and Pharmacology.

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.

R. Livingston, L. Pierce, C. Osborne, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy.

G. Hortobagyi, L. Minasian, C. Moinpour, 2012 .

Association between body mass index and response to duloxetine for aromatase inhibitor‐associated musculoskeletal symptoms in SWOG S1202

C. Moinpour, J. Unger, K. Crew, 2019, Cancer.

Omega-3 fatty acids for aromatase inhibitor–induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927).

L. Minasian, C. Moinpour, J. Unger, 2014 .

Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528.

D. Gandara, P. LoRusso, S. Gadgeel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

L. Pusztai, S. Paik, W. Barlow, 2015 .

A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

A. Gown, G. Hortobagyi, R. Livingston, 2008, Clinical breast cancer.

A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, Clinical Cancer Research.